Doctors and scientists around the world are constantly searching for better ways to treat cancer. The goal is not only to help people live longer, but also to reduce side effects and improve quality of life during and after treatment.
A new study has now brought hopeful news for men with prostate cancer by introducing a treatment that may be safer, easier to use, and gentler on the body.
The study focuses on a medicine called relugolix, an oral hormone therapy taken as a pill. Researchers believe this drug could change the way prostate cancer is treated, especially for men receiving radiation therapy. The findings were published in the medical journal JAMA Oncology.
Prostate cancer is one of the most common cancers in men. The prostate is a small gland that helps produce fluid for semen. In many cases, prostate cancer grows slowly, but some forms can become aggressive and spread to other parts of the body.
Doctors often use hormone therapy to treat prostate cancer because the disease is strongly linked to testosterone, the main male hormone. Testosterone can help prostate cancer cells grow faster, so lowering testosterone levels is an important part of treatment.
For many years, doctors have used hormone therapies such as leuprolide to reduce testosterone in prostate cancer patients. These treatments are effective, but they can also cause difficult side effects.
Low testosterone over a long period may lead to heart problems, bone weakness, tiredness, mood changes, and reduced quality of life. Because of this, researchers have been searching for treatments that can control the cancer while allowing the body to recover more quickly afterward.
Dr. Daniel Spratt, an expert in Radiation Oncology at University Hospitals Seidman Cancer Center, led the new research into relugolix.
The study examined men with both early-stage and advanced prostate cancer. It combined information from two large international clinical trials involving 260 men who received relugolix together with radiation therapy.
The results were very encouraging. Relugolix was highly effective at lowering testosterone to the target level needed for cancer treatment. After 24 weeks of therapy, 95% of the men had their testosterone reduced to the desired level.
After 48 weeks, the success rate increased to 97%. These numbers showed that the drug worked very well in controlling the hormone that fuels many prostate cancers.
One of the most important discoveries was how quickly testosterone levels recovered after men stopped taking relugolix. This recovery is important because many of the unwanted side effects of hormone therapy are linked to low testosterone. If the body can return to normal faster, patients may avoid long-term problems and feel healthier sooner after treatment ends.
The study also showed that relugolix worked just as well as leuprolide, one of the most commonly used prostate cancer treatments today. Both drugs were similarly effective at preventing prostate cancer from becoming castration-resistant prostate cancer, which is a more dangerous form that no longer responds to standard hormone treatments.
This finding suggests that relugolix may provide the same cancer control while offering benefits in recovery time and possibly fewer lasting side effects.
Safety was another important part of the research. Serious side effects were uncommon among the men taking relugolix. This is especially important because many prostate cancer patients are older and may already have heart disease or other health problems. A treatment with fewer serious risks could make cancer care safer and more manageable for many patients.
Another reason doctors are interested in relugolix is that it is taken by mouth instead of through injections. Oral medicines can often be more convenient and comfortable for patients.
Taking a pill at home may reduce hospital visits and make treatment easier to fit into daily life. Researchers also believe oral treatments may help doctors combine therapies in more flexible and effective ways in the future.
The study is part of a growing effort to improve cancer care by focusing not only on survival, but also on patient comfort and long-term health. Treatments that allow people to recover faster and avoid severe side effects can greatly improve daily life during and after cancer therapy.
Dr. Spratt is also leading another project called the OPTYX study, which is exploring how relugolix performs in everyday medical care outside of clinical trial settings.
So far, more than 600 men have joined the study, and researchers hope to include around 1,000 participants in total. This larger project will help doctors better understand how the drug works for different patients in real-world situations.
The new findings add to the growing progress being made in prostate cancer treatment. Researchers are also studying other ways to slow or stop the disease.
Some studies are examining certain bacteria that may be linked to aggressive prostate cancer, while others are testing new drug combinations to help men with advanced cancer live longer. Scientists are also working on ways to reduce the chance of cancer spreading to other parts of the body.
Although more research is still needed, relugolix appears to be a promising new option for prostate cancer patients. It may offer strong cancer control while helping men recover faster and maintain a better quality of life after treatment.
For many patients and families facing prostate cancer, this kind of progress brings new hope for safer and more comfortable care in the future.
If you care about prostate cancer, please read studies about 5 types of bacteria linked to aggressive prostate cancer, and new strategy to treat advanced prostate cancer.
For more information about prostate cancer, please see recent studies about new way to lower risk of prostate cancer spread, and results showing three-drug combo boosts survival in metastatic prostate cancer.
Copyright © 2026 Knowridge Science Report. All rights reserved.
